News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Generon (Shanghai) Corporation Ltd. Initiates a Phase I Clinical Study for F-652 in Australia


9/6/2012 7:40:14 AM

SHANGHAI--(BUSINESS WIRE)--Generon (Shanghai) Corporation Ltd. today announced the initiation of a Phase I clinical trial for F-652 in Australia. F-652 is a recombinant protein containing a human interleukin-22 (IL-22) dimer. The current Phase I study is to evaluate the safety and pharmacokinetics (PK) profile and identify biomarkers for F-652 in healthy volunteers.

Read at BioSpace.com
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES